ARCH Venture Fund IX, L.P.

13D and 13G Filings

13D/G filings: 13D on 1 security, 13G on 5 securities
Location: Chicago, IL
CIK: 0001666306
Form D filings: 2 filings
All SEC filings: View on sec.gov

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Vir Biotechnology, Inc. 13D/A Amendment 8 VIR · 92764N102	VIR	92764N102	7.3%	12,508,029	13D/A Amendment 8	11/6/2026 Event 11/4/2026
ARCH Venture Fund IX, L.P.			6.9%	11,897,988
ARCH Venture Fund IX Overage, L.P.			6.9%	11,897,988
ARCH Venture Partners IX, L.P.			6.9%	11,897,988
ARCH Venture Partners IX Overage, L.P.			6.9%	11,897,988
ARCH Venture Partners IX, LLC			6.9%	11,897,988
Robert Nelsen			7.3%	12,508,029
Keith Crandell			7.1%	12,170,952
Clinton Bybee			7.0%	11,989,718
Sana Biotechnology, Inc. 13G/A Amendment 5 SANA · 799566104	SANA	799566104	15.4%	46,173,125	13G/A Amendment 5	8/14/2026 Event 6/30/2026
ARCH Venture Fund IX, L.P.			15.3%	45,860,681
ARCH Venture Fund IX Overage, L.P.			15.3%	45,860,681
ARCH Venture Fund X, L.P.			15.3%	45,860,681
ARCH Venture Fund X Overage, L.P.			15.3%	45,860,681
ARCH Venture Partners IX, L.P.			15.3%	45,860,681
ARCH Venture Partners IX Overage, L.P.			15.3%	45,860,681
ARCH Venture Partners X Overage, L.P.			15.3%	45,860,681
ARCH Venture Partners X, L.P.			15.3%	45,860,681
ARCH Venture Partners IX, LLC			15.3%	45,860,681
ARCH Venture Partners X, LLC			15.3%	45,860,681
Keith Crandell			15.3%	45,860,681
Clinton Bybee			15.3%	45,860,681
Robert Nelsen			15.4%	46,173,125
Steven Gillis			15.3%	45,860,681
Kristina Burow			15.3%	45,860,681
Lyell Immunopharma, Inc. 13G/A Amendment 4 LYEL · 55083R203	LYEL	55083R203	13.9%	3,247,162	13G/A Amendment 4	5/15/2026 Event 3/31/2026
ARCH Venture Fund IX, L.P.			13.9%	3,247,162
ARCH Venture Fund IX Overage, L.P.			13.9%	3,247,162
ARCH Venture Fund XIII, L.P.			13.9%	3,247,162
ARCH Venture Partners IX, L.P.			13.9%	3,247,162
ARCH Venture Partners IX Overage, L.P.			13.9%	3,247,162
ARCH Venture Partners IX, LLC			13.9%	3,247,162
ARCH Venture Partners XIII, L.P.			13.9%	3,247,162
ARCH Venture Partners XIII, LLC			13.9%	3,247,162
Keith Crandell			13.9%	3,247,162
Clinton Bybee			7.8%	1,820,634
Robert Nelsen			13.9%	3,247,162
Kristina Burow			13.9%	3,247,162
Steven Gillis			13.9%	3,247,162
Paul Berns			6.1%	1,426,528
Vir Biotechnology, Inc. 13D/A Amendment 7 VIR · 92764N102	VIR	92764N102	8.5%	13,534,704	13D/A Amendment 7	3/3/2026 Event 2/27/2026
ARCH Venture Fund IX, L.P.			8.1%	12,916,663
ARCH Venture Fund IX Overage, L.P.			8.1%	12,916,663
ARCH Venture Partners IX, L.P.			8.1%	12,916,663
ARCH Venture Partners IX Overage, L.P.			8.1%	12,916,663
ARCH Venture Partners IX, LLC			8.1%	12,916,663
Robert Nelsen			8.5%	13,534,704
Keith Crandell			8.3%	13,189,627
Clinton Bybee			8.1%	13,008,393
Sana Biotechnology, Inc. 13G/A Amendment 4 SANA · 799566104	SANA	799566104	17.3%	46,093,125	13G/A Amendment 4	11/14/2025 Event 9/30/2025
ARCH Venture Fund IX, L.P.			17.2%	45,860,681
ARCH Venture Fund IX Overage, L.P.			17.2%	45,860,681
ARCH Venture Fund X, L.P.			17.2%	45,860,681
ARCH Venture Fund X Overage, L.P.			17.2%	45,860,681
ARCH Venture Partners IX, L.P.			17.2%	45,860,681
ARCH Venture Partners IX Overage, L.P.			17.2%	45,860,681
ARCH Venture Partners X Overage, L.P.			17.2%	45,860,681
ARCH Venture Partners X, L.P.			17.2%	45,860,681
ARCH Venture Partners IX, LLC			17.2%	45,860,681
ARCH Venture Partners X, LLC			17.2%	45,860,681
Keith Crandell			17.2%	45,860,681
Clinton Bybee			17.2%	45,860,681
Robert Nelsen			17.3%	46,093,125
Steven Gillis			17.2%	45,860,681
Kristina Burow			17.2%	45,860,681
Lyell Immunopharma, Inc. 13G/A Amendment 3 LYEL · 55083R203	LYEL	55083R203	13.0%	2,759,072	13G/A Amendment 3	11/14/2025 Event 9/30/2025
ARCH Venture Fund IX, L.P.			13.0%	2,759,072
ARCH Venture Fund IX Overage, L.P.			13.0%	2,759,072
ARCH Venture Fund XIII, L.P.			13.0%	2,759,072
ARCH Venture Partners IX, L.P.			13.0%	2,759,072
ARCH Venture Partners IX Overage, L.P.			13.0%	2,759,072
ARCH Venture Partners IX, LLC			13.0%	2,759,072
ARCH Venture Partners XIII, L.P.			13.0%	2,759,072
ARCH Venture Partners XIII, LLC			13.0%	2,759,072
Keith Crandell			13.0%	2,759,072
Clinton Bybee			8.6%	1,820,634
Robert Nelsen			13.0%	2,759,072
Kristina Burow			13.0%	2,759,072
Steven Gillis			13.0%	2,759,072
Paul Berns			4.4%	938,438
Singular Genomics Systems, Inc. 13G/A Amendment 1 OMIC · 82933R308	OMIC	82933R308	0%	0	13G/A Amendment 1	5/15/2025 Event 2/21/2025
ARCH Venture Fund IX, L.P.			0%	0
ARCH Venture Partners IX, L.P.			0%	0
ARCH Venture Partners IX, LLC			0%	0
Keith Crandell			0%	0
Clinton Bybee			0%	0
Robert Nelsen			0%	0
Beam Therapeutics Inc. 13G/A Amendment 4 BEAM · 07373V105	BEAM	07373V105	4.6%	4,600,747	13G/A Amendment 4	5/15/2025 Event 3/31/2025
ARCH Venture Fund IX, L.P.			4.5%	4,540,132
ARCH Venture Fund IX Overage, L.P.			4.5%	4,540,132
ARCH Venture Partners IX, L.P.			4.5%	4,540,132
ARCH Venture Partners IX Overage, L.P.			4.5%	4,540,132
ARCH Venture Partners IX, LLC			4.5%	4,540,132
Keith Crandell			4.5%	4,557,862
Clinton Bybee			4.5%	4,550,630
Robert Nelsen			4.6%	4,600,747
Lyell Immunopharma, Inc. 13G/A Amendment 2 LYEL · 55083R104	LYEL	55083R104	13.1%	36,597,716	13G/A Amendment 2	2/14/2025 Event 12/31/2024
ARCH Venture Fund IX, L.P.			13.0%	36,412,716
ARCH Venture Fund IX Overage, L.P.			13.0%	36,412,716
ARCH Venture Partners IX, L.P.			13.0%	36,412,716
ARCH Venture Partners IX Overage, L.P.			13.0%	36,412,716
ARCH Venture Partners IX, LLC			13.0%	36,412,716
Keith Crandell			13.0%	36,412,716
Clinton Bybee			13.0%	36,412,716
Robert Nelsen			13.1%	36,597,716
Beam Therapeutics Inc. 13G/A Amendment 3 BEAM · 07373V105	BEAM	07373V105	5.6%	4,600,747	13G/A Amendment 3	2/14/2025 Event 12/31/2024
ARCH Venture Fund IX, L.P.			5.5%	4,540,132
ARCH Venture Fund IX Overage, L.P.			5.5%	4,540,132
ARCH Venture Partners IX, L.P.			5.5%	4,540,132
ARCH Venture Partners IX Overage, L.P.			5.5%	4,540,132
ARCH Venture Partners IX, LLC			5.5%	4,540,132
Keith Crandell			5.5%	4,557,862
Clinton Bybee			5.5%	4,550,630
Robert Nelsen			5.6%	4,600,747

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.